Clinical Efficacy of Lenalidomide Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma  

作　　者：Yudi Miao 

机构地区：[1]Department of Hematology,Shaanxi Provincial People's Hospital,Xi'an 710068,Shaanxi Province,China

出　　处：《Proceedings of Anticancer Research》2022年第3期48-52,共5页抗癌研究

摘　　要：Objective:Multiple myeloma has a great impact on patients;the use of implant denture restorative treatment is ideal,and it is vital to carry out scientific treatment methods.Methods:The research subjects were inclusive of 60 patients with mxiltiple myeloma,who were randomly selected from January 2019 to December 2019.The patients were divided into a study group and a control group,with 30 patients in each group.The patients in the control group were treated with conventional treatment,while the patients in the study group were treated with lenalidomide combined with cyclophosphamide and dexamethasone.The effectiveness of treatment,adverse effects,and clinical indices of the two groups were compared.Results:Comparing different treatment methods,the differences in the indices between the two groups were statistically significant(p<0.05).Conclusion:The use of lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of patients with multiple myeloma increases the effectiveness of treatment and improves patientsJ clinical indices;thus,it is worthy of promotion.

关 键 词：Multiple myeloma Lenalidomide combined with cyclophosphamide and dexamethasone Conventional treatment Clinical efficacy 

分 类 号：R73[医药卫生—肿瘤]